AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$36.18
−$0.41 (−1.13%) 3:59 PM ET
After hours$36.18
+$0.00 (+0.01%) 4:33 AM ET
Prev closePrevC$36.59
OpenOpen$36.15
Day highHigh$36.50
Day lowLow$35.46
VolumeVol1,633,051
Avg volAvgVol2,358,276
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$7.55B
Sector
Healthcare
AI report sections
BULLISH
QGEN
Qiagen N.V.
QIAGEN N.V. exhibits moderately constructive technical momentum with price above key moving averages and multiple bullish pattern signals, while its longer-horizon performance over 6–12 months remains relatively flat. The balance sheet shows solid equity backing and ample current assets relative to current liabilities, though meaningful long-term debt and elevated short-volume activity introduce risk considerations. Recent news flow around end-market growth in genomics and diagnostics is broadly positive, aligning with the company’s core markets but without quantified impact on its own financial results in the provided data.
QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Qiagen N.V. for potential securities law violations. The investigation was triggered after Qiagen's Q1 2026 results showed net sales declined 1% and QuantiFERON product sales fell 5%, contradicting the company's February guidance of 6-7% growth. The stock price dropped 11% following the announcement.
Company faces federal securities investigation due to significant miss versus guidance (expected 6-7% growth but delivered -1% sales decline and -5% QuantiFERON decline), resulting in 11% stock price drop. This suggests potential misleading statements or undisclosed material information.
PositiveGlobeNewswire Inc.• Delveinsight
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight
The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.
RHHBYBDXABTQGENcervical cancer diagnosticsHPV testingliquid-based cytologyAI-powered screening
Sentiment note
Key player in molecular diagnostic technologies for cervical cancer screening
PositiveGlobeNewswire Inc.• Mordor Intelligence
Cancer Biomarkers Market Outlook 2026–2031: Growing at a 8.65% CAGR, Driven by Precision Oncology and Early Detection Demand, Says Mordor Intelligence
The cancer biomarkers market is projected to grow from USD 23.22 billion in 2026 to USD 35.16 billion by 2031, with a CAGR of 8.65%. Growth is driven by increasing cancer prevalence, rising adoption of personalized medicine, advancements in molecular diagnostics, and expanding use of companion diagnostics. North America leads the market while Asia-Pacific emerges as a high-growth region.
Identified as a major player in the expanding cancer biomarkers market. The company is positioned to benefit from growing adoption of advanced sequencing technologies and liquid biopsy platforms.
PositiveGlobeNewswire Inc.• Delveinsight
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.
Listed as key player in molecular diagnostics and precision medicine, benefiting from market expansion in biomarker-guided therapies and diagnostic innovations.
PositiveGlobeNewswire Inc.• Delveinsight
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight
The global HPV testing and Pap test market is projected to grow from USD 3.7 billion in 2025 to USD 6.5 billion by 2034, driven by rising cervical cancer prevalence, government screening initiatives, technological advancements, and the introduction of self-sampling tests. North America leads the market with 40.5% share, while Asia-Pacific emerges as a key growth hub.
RHHBYBDXQGENABTHPV testingPap testcervical cancer screeningmolecular diagnostics
Sentiment note
Major player in molecular diagnostics for HPV testing, well-positioned to benefit from increasing adoption of molecular diagnostic technologies
NegativeGlobeNewswire Inc.• Schall Law Firm
QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Qiagen N.V. for potential securities violations, alleging the company issued false or misleading statements regarding QuantiFERON growth projections. Qiagen initially guided for 6-7% growth in February 2026 but revised guidance in April to indicate largely unchanged sales levels and normalized growth only in 2027, suggesting possible investor deception.
The company is under investigation for issuing contradictory financial guidance within a two-month period, with a significant downward revision from 6-7% growth to largely unchanged sales levels. This suggests potential misrepresentation to investors and raises concerns about management credibility and internal controls.
PositiveGlobeNewswire Inc.• Healthcare Foresights
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The global Targeted DNA RNA Sequencing Market was valued at USD 8.6 billion in 2025 and is projected to reach USD 46.9 billion by 2035, growing at an 18.5% CAGR. Growth is driven by government genomic surveillance initiatives, pharmaceutical biomarker discovery, and rising demand for precision medicine. North America leads in market share while Asia Pacific shows the highest growth rate.
ILMNTMOQGENBIOtargeted DNA RNA sequencingnext-generation sequencinggenomic testingprecision medicine
Sentiment note
Listed among key market players in the expanding targeted DNA RNA sequencing sector, which is experiencing significant growth driven by pharmaceutical R&D and clinical diagnostics.
PositiveGlobeNewswire Inc.• Delveinsight
Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsight
The global metagenomics sequencing market is projected to grow from USD 2.5 billion in 2025 to USD 7.5 billion by 2034, driven by declining NGS costs, rising infectious disease burden, microbiome research expansion, and clinical diagnostic adoption. North America leads with 41% market share, while Asia-Pacific emerges as a major growth engine.
RHHBYTMOPACBQGENmetagenomics sequencingnext-generation sequencinginfectious disease diagnosticsmicrobiome research
Sentiment note
Key market player with recent product launches (May 2024 QIAseq Multimodal DNA/RNA Library Kit) supporting market expansion
NegativeGlobeNewswire Inc.• Johnson Fistel, Pllp
Coursera, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP announced investigations into potential securities law violations by Coursera, Qiagen, and Domino's Pizza on behalf of affected investors. The Coursera investigation was triggered by the company's April 23, 2026 disclosure that its Coursera for Business segment underperformed expectations, with Enterprise growth lagging Consumer growth and facing continued demand and retention pressures, resulting in stock price decline.
Company is subject to securities investigation by Johnson Fistel, indicating potential violations of federal securities laws and investor losses.
NegativeGlobeNewswire Inc.• Johnson Fistel, Pllp
Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Law firm Johnson Fistel is investigating potential securities law violations on behalf of investors in Qiagen N.V., Domino's Pizza, Inc., and Hamilton Lane Incorporated. The investigation into Qiagen was triggered by the company's April 27, 2026 announcement of declining net sales (down 1% CER), reduced full-year 2026 outlook (1-2% growth), and a significant decline in immigration testing demand affecting its QuantiFERON product, which caused the stock to drop approximately 10%.
QGENDPZsecurities fraudinvestor lossesclass action investigationstock declineearnings miss
Sentiment note
Company disclosed weaker-than-expected Q1 2026 results with net sales declining 1% CER, QuantiFERON product sales down 5% CER, and significantly reduced full-year guidance to 1-2% growth due to declining immigration testing demand. Stock price fell approximately 10% following the announcement, triggering a securities investigation.
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - Asia-Pacific NGS Market Poised for Fastest Growth, Driven by Large-Scale Genomic Projects and the Rising Need for Precision Medicine
The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic and research institutes lead the services end-user segment.
As a leading NGS company specializing in sample preparation and bioinformatics tools, well-positioned to benefit from increased demand for consumables and enhanced data analysis solutions.
PositiveGlobeNewswire Inc.• Sns Insider
Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider
The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.
Qiagen is listed among major players in a rapidly expanding market with a projected CAGR of 9.07%, benefiting from growing adoption of molecular diagnostic technologies.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
